Protein component of ribonuclease P (RnpA) has been identified as a promising new drug discovery target for methicillin-resistant S. aureus (MRSA). RnpA is an essential protein that is thought to perform two required cellular processes. As part of the RNA degrasome Rnpa mediates RNA degradation. In combination with rnpB it forms RNase P haloenzymes which are required for tRNA maturation. As part of an effort to develop novel therapies for MRSA infection, we have identified novel compounds that inhibit RnpA and display synergistic activity in vitro when used in combination with mupirocin, an antibiotic used for decolonizing MSRA whose effectiveness has recently been jeopardized by bacterial resistance. These findings represent an opportunity to develop novel compounds capable of re-sensitizing mupirocin-resistant bacteria to mupirocin.
Moulder Center for Drug Discovery Research
Temple University School of Pharmacy
3307 N Broad Street
Philadelphia, PA 19140